Infanrix And Infanrix-hexa Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The infanrix and infanrix-hexa market research report is one of a series of new reports that provides infanrix and infanrix-hexa market statistics, including the infanrix and infanrix-hexa industry's global market size, regional shares, competitors with an infanrix and infanrix-hexa market share, detailed infanrix and infanrix-hexa market segments, market trends and opportunities, and any further data you may need to thrive in the infanrix and infanrix-hexa industry. This infanrix and infanrix-hexa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to increasing global immunization initiatives, rising prevalence of vaccine-preventable diseases, expanding healthcare access in emerging economies, supportive government policies and funding, and growing awareness about pediatric immunization. Major trends in the forecast period include advancements in cold chain logistics, integration with digital vaccination tracking systems, innovation in formulations, advancements in vaccine delivery technologies, and advancements in combination vaccines.

The growing number of pertussis cases is expected to drive the growth of the Infanrix and Infanrix-Hexa vaccine market. Pertussis, also known as whooping cough, is a highly contagious respiratory disease, and the prevalence of the condition has been rising due to factors such as lower vaccination rates, changes in immunity, and an increase in undiagnosed or misdiagnosed cases. As pertussis cases rise, the demand for Infanrix and Infanrix-Hexa vaccines increases since these vaccines effectively prevent the disease. For example, in October 2024, the Health Protection Surveillance Centre in Ireland reported 514 pertussis cases, a significant increase from the 18 cases in 2023, and much higher than the 7 cases in 2022 and 5 cases in 2021. This increase in pertussis cases is expected to drive the demand for these vaccines, fueling market growth.

The growth of the Infanrix and Infanrix-Hexa market is also anticipated to be influenced by rising healthcare expenditure. As healthcare spending rises, driven by factors such as an aging population, increasing healthcare needs, advancements in medical technology, and the higher costs of services and medications, more resources are allocated to healthcare services. This increased spending will support immunization efforts, thereby improving vaccine availability and facilitating the growth of the Infanrix and Infanrix-Hexa market. For example, in May 2024, the Office for National Statistics in the UK reported a 5.6% increase in healthcare expenditure from 2022 to 2023, compared to a 0.9% growth in the previous year. This increase in healthcare expenditure is expected to further drive the market for Infanrix and Infanrix-Hexa vaccines.

The rising number of child deaths is also expected to contribute to the growth of the Infanrix and Infanrix-Hexa vaccine market. Child death rates refer to the number of children who die under the age of 15 within a specific time frame, and the increase in child mortality is linked to factors such as malnutrition, inadequate healthcare, infectious diseases, poor hygiene, and economic challenges. The Infanrix and Infanrix-Hexa vaccines help reduce child mortality by protecting children from multiple life-threatening diseases. For instance, in May 2024, the Office for National Statistics reported that there were 2,349 infant deaths and 1,019 child deaths in 2022, an increase from the previous year’s numbers. As child mortality rates rise, the demand for vaccines such as Infanrix and Infanrix-Hexa is expected to increase, driving market growth.

The key company operating in the infanrix and infanrix-hexa market is GlaxoSmithKline plc.

North America was the largest region in the infanrix and infanrix-hexa market in 2024. The regions covered in infanrix and infanrix-hexa report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the infanrix and infanrix-hexa market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Infanrix and Infanrix-hexa are vaccines designed to protect infants and young children from several serious infectious diseases. Infanrix is a vaccine that provides protection against diphtheria, tetanus, and whooping cough (pertussis), and is administered in multiple doses starting at 2 months of age to help prevent these infections. In contrast, Infanrix-hexa is a combination vaccine that provides protection against six diseases: diphtheria, tetanus, whooping cough, polio, hepatitis B, and Haemophilus influenzae type b (Hib).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary patient demographics for Infanrix and Infanrix-hexa include infants, children, adolescents, and adults. Infants, referring to children under 1 year of age, are particularly protected by these vaccines, which prevent multiple infectious diseases. These vaccines are used for clinical indications such as diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis, and Haemophilus influenzae type b (Hib). They are distributed through various channels including hospitals, clinics, public health programs, and pharmacies, with applications in primary vaccination, booster doses, and in combination with other vaccines.

The infanrix and infanrix-hexa market consists of sales of Infanrix vaccines for diphtheria, tetanus, and whooping cough, Infanrix-hexa vaccines for diphtheria, tetanus, whooping cough, polio, hepatitis B, and Haemophilus influenzae type b and combination vaccines for infants and young children to protect against multiple infectious diseases. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.